42 patents
Page 2 of 3
Utility
Methods for Quantitation of Functional C1 Esterase Inhibitor (FC1-INH)
4 Nov 20
Methods for quantitation of fC1-INH from dried blood spot are provided herein.
Priya Sethu Chockalingam, Yongquan Lai, Jiang Wu, Guodong Zhang, Zhiwei Zhou
Filed: 14 Apr 20
Utility
Libraries of Genetic Packages Comprising Novel HC CDR1, CDR2, and CDR3 and Novel LC CDR1, CDR2, and CDR3 Designs
4 Nov 20
Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme.
Robert Charles Ladner
Filed: 1 Apr 20
Utility
Lateral Flow Immunoassay for Measuring Functional C1-ESTERASE Inhibitor (C1-INH) In Plasma Samples
28 Oct 20
A device for detecting and/or quantifying functional C1-esterase inhibitor (fC1-INH), the device comprising: (i) a conjugate pad comprising a first zone and a second zone, on which a first agent and a second agent are immobilized, respectively, and (ii) a membrane, which is in communication with the conjugate pad, wherein the membrane comprises a third zone, on which a third agent is immobilized.
Priya Sethu Chockalingam, Zhiwei Zhou
Filed: 8 Apr 20
Utility
Focused Libraries of Genetic Packages
14 Oct 20
Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family.
Robert Charles Ladner
Filed: 12 Feb 20
Utility
Plasma Kallikrein Inhibitors and Uses Thereof for Treating Hereditary Angioedema Attack
7 Oct 20
Provided herein are methods of treating and preventing hereditary angioedema attack in certain human patient subpopulations whose disease is well controlled in a first treatment period, which involves the use of an antibody that binds human plasma kallikrein.
Joan Yesid Mendivil Medina
Filed: 12 Mar 20
Utility
Inhibitors of Plasma Kallikrein and Uses Thereof
29 Jul 20
Jeremy Travins, Thomas Miller, Nikolaos Papaioannou
Filed: 2 Aug 18
Utility
Display Library Process
22 Jul 20
Disclosed are methods for identifying desired members from a display libraries, including bacteriophage display libraries.
Robert Charles Ladner, Shannon Hogan, Kristin L. Rookey
Filed: 20 Jan 20
Utility
Libraries of genetic packages comprising novel HC CDR3 designs
20 Jul 20
Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme.
Robert Charles Ladner
Filed: 7 Dec 17
Utility
Assays for determining levels of plasma protease C1 inhibitor
22 Jun 20
The invention provides assay methods of detecting plasma protease CI inhibitor (Cl-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder.
Kusumam Joseph, Allen P. Kaplan
Filed: 16 Jan 14
Utility
Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
15 Jun 20
Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme.
Robert Charles Ladner
Filed: 7 Jun 16
Utility
Diagnosis and treatment of autoimmune diseases
11 May 20
Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.
Daniel J. Sexton, Burt Adelman, Andrew Nixon
Filed: 13 Sep 18
Utility
Compositions and Methods for Treatment of Diabetic Macular Edema
15 Apr 20
Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
Filed: 14 Aug 19
Utility
Plasma Kallikrein Binding Proteins
8 Apr 20
Plasma kallikrein binding proteins and methods of using such proteins are described.
Daniel J. Sexton, Malini Viswanathan
Filed: 13 May 19
Utility
Plasma Kallikrein Inhibitors and Uses Thereof for Treating Hereditary Angioedema Attack
8 Apr 20
Provided herein are methods of treating and preventing hereditary angioedema attack in certain human patient subpopulations using antibodies binding to active plasma kallikrein with specific treatment regimens, for example, at about 300 mg every two weeks.
Peng Lu, Christina Nurse, Xinming Hao
Filed: 29 Aug 19
Utility
FC Receptor Binding Proteins
8 Apr 20
The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
Filed: 6 Oct 19
Utility
Focused libraries of genetic packages
30 Mar 20
Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family.
Robert Charles Ladner
Filed: 29 Oct 17
Utility
Display library process
2 Mar 20
Disclosed are methods for identifying desired members from a display libraries, including bacteriophage display libraries.
Robert Charles Ladner, Shannon Hogan, Kristin L. Rookey
Filed: 25 May 17
Utility
Multi-chain eukaryotic display vectors and uses thereof
2 Mar 20
A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell.
Simon E. Hufton, Hendricus Renerus Jacobus Mattheus Hoogenboom
Filed: 22 Jul 18
Utility
Plasma Kallikrein Binding Proteins
15 Jan 20
Plasma kallikrein binding proteins and methods of using such proteins are described.
Daniel J. Sexton, Malini Viswanathan
Filed: 18 Jun 19
Utility
Metabolite Biomarkers for Diseases Associated with the Contact Activation System
27 Nov 19
Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
Filed: 14 Sep 17